pyrC Gene Complementation for Antibiotic-Free Plasmid Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current heterologous protein expression systems in Escherichia coli rely on antibiotic resistance for plasmid stabilization, which is not GMP compliant and leads to plasmid loss, reducing recombinant protein yield, especially in minimal media used for human protein production.
Innovation Solution
A novel host/vector system based on pyrC gene complementation, where the pyrC gene is deleted from the host chromosome and cloned onto the expression vector, creating a selective pressure that requires pyrimidine synthesis, ensuring plasmid stability and high recombinant protein production without antibiotics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If antibiotic resistance genes are used for plasmid stabilization, then plasmid maintenance is improved, but GMP compliance and protein yield are worsened
Solution Approach 1:
The invention extracts the selection mechanism from antibiotic-based systems and replaces it with an antibiotic-free auxotrophic complementation system. The pyrC gene is moved from the host chromosome to the plasmid, creating a plasmid-dependent selection system that maintains plasmid stability without requiring antibiotics, thus achieving both plasmid stability and GMP compliance
Solution Approach 2:
The invention changes the selection parameter from antibiotic resistance to auxotrophic complementation. By deleting pyrC from the host chromosome and placing it on the plasmid, the system shifts from chemical selection (antibiotics) to metabolic selection (uracil auxotrophy), eliminating antibiotic residues while maintaining selective pressure for plasmid retention
2Stability of the object's composition
If antibiotics are used during culture growth, then plasmid loss is prevented, but protein yield in minimal media is reduced
Solution Approach 1:
The invention removes antibiotics from the culture system and replaces them with a plasmid-based auxotrophic complementation system. The pyrC gene on the plasmid complements the host's pyrC deletion, creating a dependency where only plasmid-containing cells can grow in minimal media, thus preventing plasmid loss without antibiotic interference
Solution Approach 2:
The plasmid carries its own selection mechanism through the pyrC gene, which provides the host with the ability to synthesize pyrimidines. This self-contained system eliminates the need for external antibiotics, allowing the plasmid to ensure its own maintenance through metabolic complementation
3Stability of the object's composition
If ampicillin concentration is increased to prevent delayed growth, then culture homogeneity is improved, but plasmid stability is worsened due to metabolic burden
Solution Approach 1:
The invention replaces the mechanical/chemical system of antibiotic selection with a metabolic system of auxotrophic complementation. Instead of using ampicillin's chemical mechanism to maintain homogeneity, the system uses the pyrC gene product to restore pyrimidine synthesis capability, creating a more efficient selection mechanism with lower metabolic burden
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This system maintains high plasmid stability and recombinant protein yield, even under conditions of high metabolic stress, outperforming traditional antibiotic-based systems and enabling efficient production of proteins like human antibodies in industrial-scale fermentations.
Implementation Method 1
The gene pyrC encodes the enzyme dihydroorotase which catalyses the conversion of dihydroorotate to orotate, an intermediate in the biosynthesis of pyrimidines
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a method of producing a recombinant protein comprising using a selection method other than antibiotics. In particular, it relates to a stable host/vector system based on the pyrC gene complementation designed to produce high level of heterologous recombinant protein in Escherichia coli. The expression system of the present invention allows rapid selection of plasmid containing cells during the cloning phases and lead to high protein expression during fermentation. This system has a strong selective efficiency, especially during the induction phase, leading to the selection of an almost homogeneous and stable plasmid bearing cell population. Moreover the productivity of the culture is to a large extent better than the one based on antibiotic resistance. This elevated vector stability combined with its high productivity fulfils the requirements for heterologous protein production in Escherichia coli to an industrial level.